BioSpace News Archive

Kura Oncology, Inc. today reported proof of mechanism in KURRENT-HN, the Company’s Phase 1/2 clinical trial of tipifarnib in combination with alpelisib in patients with HRAS- and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC).

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.

Flare Therapeutics today presented new preclinical data in a poster presentation.

Medable Inc. , the industry-leading technology platform for patient-centered clinical trials, today announced a new patient-first oncology offering that enables life sciences companies to improve patient access, enrollment, and retention in cancer trials.

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced the appointment of Mark Baldry to the position of Chief Commercial Officer.

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced it has completed enrollment for the second cohort of a three cohort Phase 1b clinical trial of zotatifin in non-hospitalized adults with confirmed COVID-19 infection.

Sema4, a health insights company, has collaborated on research debunking a commonly held belief that exome and genome sequencing deliver more inconclusive results than multi-gene panels.

Candel Therapeutics, Inc. (Nasdaq: CADL) (Candel or the Company), a clinical stage biopharmaceutical company developing viral immunotherapies, today announced a collaboration with the University of Pennsylvania (Penn) to study the impact of novel viral immunotherapies based on Candel’s proprietary enLIGHTEN™ Discovery Platform to strengthen the effects of Penn’s CAR-T cell therapies in solid tumor models.

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) today announced the presentation of three posters reporting new preclinical data on BDTX-1535 and BDTX-4933 at the 34th European Organisation for Research and Treatment of Cancer—National Cancer Institute—American Association for Cancer Research (EORTC-NCI-AACR) Symposium on Molecular Targets and Cancer Therapeutics being held in Barcelona, Spain.

Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, November 2, 2022, at 4:30 p.m. Eastern Time (ET) to review its third quarter 2022 financial results and provide a business update.